- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Copiktra
Synonyms :
duvelisib
Class :
Antineoplastics and PI3K Inhibitors
Dosage Forms & Strengths
capsule
15mg
25mg
chronic lymphocytic leukemia (Cll)
25
mg
Oral
two times a day in 28-day cycles
Capsule
Continue the therapy until unacceptable toxicity or progressive disease occurs
Safety and efficacy are not studied
Refer adult dosing
may diminish the concentration of serum when combined with duvelisib
may diminish the concentration of serum when combined with duvelisib
may increase the QTc prolonging effect of QT-prolonging agents
duvelisib: they may diminish the serum concentration of CYP3A4 Inducers
duvelisib: they may diminish the serum concentration of CYP3A4 Inducers
duvelisib: they may diminish the serum concentration of CYP3A4 Inducers
duvelisib: they may diminish the serum concentration of CYP3A4 Inducers
duvelisib: they may diminish the serum concentration of CYP3A4 Inducers
nafcillin will decrease the effect of action of duvelisib by affecting enzyme CYP3A4 metabolism.
It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
It may enhance the effect when combined with irinotecan liposomal by affecting CYP3A4 metabolism
It may enhance the levels when combined with tamsulosin by affecting CYP3A4 metabolism
the effect of duvelisib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may enhance serum concentration and therapeutic effects of docetaxel
duvelisib increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
Frequency defined
>10%
Edema
Skin rash
Stevens-Johnsons syndrome
Hyperkalemia
hypoalbuminemia
hypocalcemia hypokalemia
Abdominal pain
colitis
constipation
decreased appetite
nausea
stomatitis
vomiting
Anemia
leukopenia
lymphocytopenia
lymphocytosis
neutropenia
thrombocytopenia
1-10%
Cytomegalovirus disease
Arthralgia
Pregnancy warnings:
US FDA pregnancy category: Not assigned
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: duvelisib (Rx)
Pronounced: du-velis-i-b
Why do we use duvelisib?
duvelisib is an anticancer drug used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).